StemRIM Announces Patent Registration for the Use of Redasemtide as an Additional Treatment for Cardiomyopathy and Old Myocardial Infarction
development, and believe that the granting of this patent will ensure the possibility of developing a drug for cardiomyopathy, old myocardial infarction, and chronic heart failure in
China. To date, it have been granted many patents for HMGB1 fragment peptides (including Redasemtide) in Japan, the U.S., Europe, and other countries around the world, including substance patents and medical use patents. The impact on the financial performance for the fiscal year ending July 31, 2024, is insignificant.